Yeager A M
Johns Hopkins Oncology Center, Baltimore, MD 21205.
Md Med J. 1990 Apr;39(4):337-41.
Allogeneic bone marrow transplantation is a therapeutic option for enzyme replacement in children with lysosomal storage diseases, for which no current conventional treatments are curative. Although marrow allografting is costly, intensive, and not risk free, strides are being made in the management and prevention of procedure-related complications.
同种异体骨髓移植是溶酶体贮积症患儿酶替代治疗的一种选择，目前尚无传统治疗方法可治愈该疾病。尽管骨髓移植成本高昂、强度大且并非毫无风险，但在与手术相关并发症的管理和预防方面正取得进展。
